• Início
  • Resultados da busca
  • A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

The Journal of urology (2013-10-19)
Joseph R Osborne, David A Green, Daniel E Spratt, Serge Lyashchenko, Shoaib B Fareedy, Brian D Robinson, Bradley J Beattie, Manu Jain, Jason S Lewis, Paul Christos, Steven M Larson, Neil H Bander, Douglas S Scherr
RESUMO

In this pilot study we explored the feasibility of (89)Zr labeled J591 monoclonal antibody positron emission tomography of localized prostate cancer. Before scheduled radical prostatectomy 11 patients were injected intravenously with (89)Zr-J591, followed 6 days later by whole body positron emission tomography. Patients underwent surgery the day after imaging. Specimens were imaged by ex vivo micro positron emission tomography and a custom 3 Tesla magnetic resonance scanner coil. Positron emission tomography images and histopathology were correlated. Median patient age was 61 years (range 47 to 68), median prostate specific antigen was 5.2 ng/ml (range 3.5 to 12.0) and median biopsy Gleason score of the 11 index lesions was 7 (range 7 to 9). On histopathology 22 lesions were identified. Median lesion size was 5.5 mm (range 2 to 21) and median Gleason score after radical prostatectomy was 7 (range 6 to 9). Eight of 11 index lesions (72.7%) were identified by in vivo positron emission tomography. Lesion identification improved with increasing lesion size for in vivo and ex vivo positron emission tomography (each p <0.0001), and increasing Gleason score (p = 0.14 and 0.01, respectively). Standardized uptake values appeared to correlate with increased Gleason score but not significantly (p = 0.19). To our knowledge this is the first report of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in localized prostate cancer cases. In this setting (89)Zr-J591 bound to tumor foci in situ and positron emission tomography identified primarily Gleason score 7 or greater and larger tumors, likely corresponding to clinically significant disease warranting definitive therapy. A future, larger clinical validation trial is planned to better define the usefulness of (89)Zr-J591 positron emission tomography for localized prostate cancer.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Zirconium, powder, −100 mesh
Sigma-Aldrich
Zirconium, foil, thickness 0.1 mm, 99.98% trace metals basis
Sigma-Aldrich
Zirconium, sponge, ≥99% trace metals basis
Sigma-Aldrich
Zirconium, rod, diam. 6.35 mm, ≥99% trace metals basis
Zirconium, rod, 100mm, diameter 50mm, centerless ground, 99.2%
Zirconium, foil, not light tested, 50x50mm, thickness 0.006mm, 99.2%
Zirconium, rod, 1000mm, diameter 1.5mm, 99.2%
Zirconium, rod, 1000mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 6.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 1.5mm, 99.2%
Zirconium, rod, 100mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 19.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 6.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 1.5mm, 99.2%
Zirconium, rod, 200mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 19.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 6.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 500mm, diameter 1.5mm, 99.2%

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.